Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
Zacks
More News
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?
TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.read more...
Benzinga
TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data
Recent announcements from TG Therapeutics have buoyed optimism on the long-term potential of its Briumvi drug.
Stocktwits
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
Zacks
TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle Disease
TGTX’s early-stage study showed the injectable form of BRIUMVI delivered quick and meaningful symptom relief in most myasthenia gravis patients.
Stocktwits
Why Is TG Therapeutics Stock Gaining Tuesday?
TGTX stock rises on positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis. See what's next for TG Therapeutics.read more...
Benzinga
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.